GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genesystem Co Ltd (XKRX:363250) » Definitions » EV-to-EBIT

Genesystem Co (XKRX:363250) EV-to-EBIT : -5.52 (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genesystem Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genesystem Co's Enterprise Value is ₩32,119.2 Mil. Genesystem Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-5,818.8 Mil. Therefore, Genesystem Co's EV-to-EBIT for today is -5.52.

The historical rank and industry rank for Genesystem Co's EV-to-EBIT or its related term are showing as below:

XKRX:363250' s EV-to-EBIT Range Over the Past 10 Years
Min: -242.07   Med: -5.33   Max: 34.33
Current: -5.52

During the past 5 years, the highest EV-to-EBIT of Genesystem Co was 34.33. The lowest was -242.07. And the median was -5.33.

XKRX:363250's EV-to-EBIT is ranked worse than
100% of 100 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.38 vs XKRX:363250: -5.52

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genesystem Co's Enterprise Value for the quarter that ended in Mar. 2024 was ₩64,106.4 Mil. Genesystem Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-5,818.8 Mil. Genesystem Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -9.08%.


Genesystem Co EV-to-EBIT Historical Data

The historical data trend for Genesystem Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genesystem Co EV-to-EBIT Chart

Genesystem Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - 13.91 -5.11 -7.52

Genesystem Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.50 -17.98 -16.54 -7.52 -11.02

Competitive Comparison of Genesystem Co's EV-to-EBIT

For the Diagnostics & Research subindustry, Genesystem Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genesystem Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genesystem Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genesystem Co's EV-to-EBIT falls into.



Genesystem Co EV-to-EBIT Calculation

Genesystem Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=32119.221/-5818.764
=-5.52

Genesystem Co's current Enterprise Value is ₩32,119.2 Mil.
Genesystem Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,818.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genesystem Co  (XKRX:363250) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genesystem Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-5818.764/64106.3966
=-9.08 %

Genesystem Co's Enterprise Value for the quarter that ended in Mar. 2024 was ₩64,106.4 Mil.
Genesystem Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,818.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genesystem Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genesystem Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genesystem Co (XKRX:363250) Business Description

Traded in Other Exchanges
N/A
Address
200-9, Techno 2-ro, Yuseong-gu, Daejeon, KOR, 34028
Genesystem Co Ltd is a biotech engineering company specializing in molecular testing solutions that target on-site testing needs. It develops and markets state-of-the-art PCR platforms as well as related reagents and biochip products designed to enhance the health of human societies and improve the quality of human life.

Genesystem Co (XKRX:363250) Headlines

No Headlines